Age 0 3 0 3 B-age
≥ 4 5 4 5 O
18 6 8 6 8 B-lower_bound
years 9 14 9 14 I-lower_bound

Any 0 3 15 18 O
serious 4 11 19 26 O
uncontrolled 12 24 27 39 O
medical 25 32 40 47 B-chronic_disease
disorder 33 41 48 56 I-chronic_disease
that 42 46 57 61 O
would 47 52 62 67 O
impair 53 59 68 74 O
the 60 63 75 78 O
ability 64 71 79 86 O
of 72 74 87 89 O
the 75 78 90 93 O
subject 79 86 94 101 O
to 87 89 102 104 O
receive 90 97 105 112 O
protocol 98 106 113 121 B-treatment
- 106 107 121 122 I-treatment
driven 107 113 122 128 I-treatment
therapy 114 121 129 136 I-treatment

Core 0 4 137 141 B-treatment
biopsy 5 11 142 148 I-treatment
or 12 14 149 151 O
other 15 20 152 157 O
minor 21 26 158 163 B-treatment
surgical 27 35 164 172 I-treatment
procedure 36 45 173 182 I-treatment

Eastern 0 7 183 190 B-chronic_disease
Cooperative 8 19 191 202 I-chronic_disease
Oncology 20 28 203 211 I-chronic_disease
Group 29 34 212 217 I-chronic_disease
( 35 36 218 219 I-chronic_disease
ECOG 36 40 219 223 I-chronic_disease
) 40 41 223 224 I-chronic_disease
performance 42 53 225 236 I-chronic_disease
status 54 60 237 243 I-chronic_disease
≤ 61 62 244 245 O
2 63 64 246 247 B-upper_bound

Evidence 0 8 248 256 O
of 9 11 257 259 O
bleeding 12 20 260 268 B-chronic_disease
diathesis 21 30 269 278 I-chronic_disease
or 31 33 279 281 O
significant 34 45 282 293 O
coagulopathy 46 58 294 306 B-chronic_disease
( 59 60 307 308 O
in 60 62 308 310 O
the 63 66 311 314 O
absence 67 74 315 322 O
of 75 77 323 325 O
therapeutic 78 89 326 337 B-treatment
anticoagulation 90 105 338 353 I-treatment
) 105 106 353 354 O

Histological 0 12 355 367 O
or 13 15 368 370 O
cytological 16 27 371 382 O
documentation 28 41 383 396 O
of 42 44 397 399 O
adenocarcinoma 45 59 400 414 B-cancer
of 60 62 415 417 O
the 63 66 418 421 O
colon 67 72 422 427 O
or 73 75 428 430 O
rectum 76 82 431 437 O

History 0 7 438 445 O
of 8 10 446 448 O
abdominal 11 20 449 458 O
fistula 21 28 459 466 O
or 29 31 467 469 O
gastrointestinal 32 48 470 486 B-chronic_disease
perforation 49 60 487 498 I-chronic_disease
within 61 67 499 505 O
6 68 69 506 507 B-upper_bound
months 70 76 508 514 I-upper_bound
prior 77 82 515 520 O
to 83 85 521 523 O
Day 86 89 524 527 O
1 90 91 528 529 O
of 92 94 530 532 O
FOLFIRI 95 102 533 540 B-treatment
+ 103 104 541 542 O
bevacizumab 105 116 543 554 B-treatment
initiation 117 127 555 565 I-treatment

History 0 7 566 573 O
of 8 10 574 576 O
hemoptysis 11 21 577 587 B-chronic_disease
( 22 23 588 589 O
≥ 23 24 589 590 O
1/2 25 28 591 594 B-lower_bound
teaspoon 29 37 595 603 I-lower_bound
of 38 40 604 606 O
bright 41 47 607 613 B-clinical_variable
red 48 51 614 617 I-clinical_variable
blood 52 57 618 623 I-clinical_variable
per 58 61 624 627 O
episode 62 69 628 635 O
) 69 70 635 636 O
within 71 77 637 643 O
1 78 79 644 645 B-upper_bound
month 80 85 646 651 I-upper_bound
prior 86 91 652 657 I-upper_bound
to 92 94 658 660 O
Day 95 98 661 664 O
1 99 100 665 666 O
of 101 103 667 669 O
FOLFIRI 104 111 670 677 B-treatment
+ 112 113 678 679 I-treatment
bevacizumab 114 125 680 691 I-treatment
initiation 126 136 692 702 O

Inadequately 0 12 703 715 O
controlled 13 23 716 726 O
hypertension 24 36 727 739 B-chronic_disease
( 37 38 740 741 O
defined 38 45 741 748 O
as 46 48 749 751 O
systolic 49 57 752 760 B-clinical_variable
blood 58 63 761 766 I-clinical_variable
pressure 64 72 767 775 I-clinical_variable
> 73 74 776 777 O
140 75 78 778 781 B-lower_bound
mmHg 79 83 782 786 I-lower_bound
and/or 84 90 787 793 O
diastolic 91 100 794 803 B-clinical_variable
blood 101 106 804 809 I-clinical_variable
pressure 107 115 810 818 I-clinical_variable
> 116 117 819 820 O
90 118 120 821 823 B-lower_bound
mmHg 121 125 824 828 I-lower_bound
) 125 126 828 829 O

Known 0 5 830 835 O
dihydropyrimidine 6 23 836 853 B-chronic_disease
dehydrogenase 24 37 854 867 I-chronic_disease
( 38 39 868 869 I-chronic_disease
DPD 39 42 869 872 I-chronic_disease
) 42 43 872 873 I-chronic_disease
deficiency 44 54 874 884 I-chronic_disease

Major 0 5 885 890 B-treatment
surgical 6 14 891 899 I-treatment
procedure 15 24 900 909 I-treatment
, 24 25 909 910 O
open 26 30 911 915 B-treatment
biopsy 31 37 916 922 I-treatment
, 37 38 922 923 O
or 39 41 924 926 O
significant 42 53 927 938 O
traumatic 54 63 939 948 B-chronic_disease
injury 64 70 949 955 I-chronic_disease
within 71 77 956 962 O
28 78 80 963 965 B-upper_bound
days 81 85 966 970 I-upper_bound
prior 86 91 971 976 I-upper_bound
to 92 94 977 979 O
Day 95 98 980 983 O
1 99 100 984 985 O
of 101 103 986 988 O
FOLFIRI 104 111 989 996 B-treatment
+ 112 113 997 998 I-treatment
bevacizumab 114 125 999 1010 I-treatment
initiation 126 136 1011 1021 I-treatment
or 137 139 1022 1024 O
anticipation 140 152 1025 1037 O
of 153 155 1038 1040 O
need 156 160 1041 1045 O
for 161 164 1046 1049 O
major 165 170 1050 1055 B-treatment
surgical 171 179 1056 1064 I-treatment
procedure 180 189 1065 1074 I-treatment
during 190 196 1075 1081 O
the 197 200 1082 1085 O
course 201 207 1086 1092 O
of 208 210 1093 1095 O
the 211 214 1096 1099 O
study 215 220 1100 1105 O

Metastatic 0 10 1106 1116 B-cancer
disease 11 18 1117 1124 I-cancer
not 19 22 1125 1128 O
amenable 23 31 1129 1137 O
to 32 34 1138 1140 O
surgical 35 43 1141 1149 B-treatment
resection 44 53 1150 1159 I-treatment
with 54 58 1160 1164 I-treatment
curative 59 67 1165 1173 I-treatment
intent 68 74 1174 1180 I-treatment

Negative 0 8 1181 1189 B-pregnancy
pregnancy 9 18 1190 1199 I-pregnancy
test 19 23 1200 1204 O
( 24 25 1205 1206 O
urine 25 30 1206 1211 O
or 31 33 1212 1214 O
serum 34 39 1215 1220 O
) 39 40 1220 1221 O
, 40 41 1221 1222 O
within 42 48 1223 1229 O
7 49 50 1230 1231 B-upper_bound
day 51 54 1232 1235 I-upper_bound
prior 55 60 1236 1241 I-upper_bound
to 61 63 1242 1244 O
Day 64 67 1245 1248 O
1 68 69 1249 1250 O
of 70 72 1251 1253 O
FOLFIRI 73 80 1254 1261 O
in 81 83 1262 1264 O
women 84 89 1265 1270 B-gender
of 90 92 1271 1273 O
childbearing 93 105 1274 1286 O
potential 106 115 1287 1296 O

No 0 2 1297 1299 O
prior 3 8 1300 1305 B-treatment
chemotherapy 9 21 1306 1318 I-treatment
for 22 25 1319 1322 O
metastatic 26 36 1323 1333 B-cancer
disease 37 44 1334 1341 I-cancer

Other 0 5 1342 1347 O
anti 6 10 1348 1352 B-treatment
- 10 11 1352 1353 I-treatment
cancer 11 17 1353 1359 I-treatment
or 18 20 1360 1362 I-treatment
investigational 21 36 1363 1378 I-treatment
therapy 37 44 1379 1386 I-treatment
while 45 50 1387 1392 O
patients 51 59 1393 1401 O
are 60 63 1402 1405 O
on 64 66 1406 1408 O
study 67 72 1409 1414 O
therapy 73 80 1415 1422 O

Prior 0 5 1423 1428 O
history 6 13 1429 1436 O
of 14 16 1437 1439 O
hypertensive 17 29 1440 1452 B-chronic_disease
encephalopathy 30 44 1453 1467 I-chronic_disease

Prior 0 5 1468 1473 B-treatment
treatment 6 15 1474 1483 I-treatment
with 16 20 1484 1488 O
irinotecan 21 31 1489 1499 B-treatment
and/or 32 38 1500 1506 O
bevacizumab 39 50 1507 1518 B-treatment

Serious 0 7 1519 1526 O
, 7 8 1526 1527 O
non 9 12 1528 1531 O
- 12 13 1531 1532 O
healing 13 20 1532 1539 O
wound 21 26 1540 1545 O
, 26 27 1545 1546 O
active 28 34 1547 1553 O
ulcer 35 40 1554 1559 B-chronic_disease
, 40 41 1559 1560 O
or 42 44 1561 1563 O
untreated 45 54 1564 1573 O
bone 55 59 1574 1578 O
fracture 60 68 1579 1587 O

Significant 0 11 1588 1599 O
vascular 12 20 1600 1608 B-chronic_disease
disease 21 28 1609 1616 I-chronic_disease
( 29 30 1617 1618 O
e.g. 30 34 1618 1622 O
, 34 35 1622 1623 O
aortic 36 42 1624 1630 B-treatment
aneurysm 43 51 1631 1639 I-treatment
, 51 52 1639 1640 O
requiring 53 62 1641 1650 O
surgical 63 71 1651 1659 B-treatment
repair 72 78 1660 1666 I-treatment
or 79 81 1667 1669 O
recent 82 88 1670 1676 O
peripheral 89 99 1677 1687 O
arterial 100 108 1688 1696 B-chronic_disease
thrombosis 109 119 1697 1707 I-chronic_disease
) 119 120 1707 1708 O
within 121 127 1709 1715 O
6 128 129 1716 1717 B-upper_bound
months 130 136 1718 1724 I-upper_bound
prior 137 142 1725 1730 I-upper_bound
to 143 145 1731 1733 O
Day 146 149 1734 1737 O
1 150 151 1738 1739 O
of 152 154 1740 1742 O
FOLFIRI 155 162 1743 1750 B-treatment
+ 163 164 1751 1752 O
bevacizumab 165 176 1753 1764 B-treatment
initiation 177 187 1765 1775 O

Unable 0 6 1776 1782 O
or 7 9 1783 1785 O
unwilling 10 19 1786 1795 O
to 20 22 1796 1798 O
discontinue 23 34 1799 1810 O
( 35 36 1811 1812 O
and 36 39 1812 1815 O
substitute 40 50 1816 1826 O
if 51 53 1827 1829 O
necessary 54 63 1830 1839 O
) 63 64 1839 1840 O
use 65 68 1841 1844 O
of 69 71 1845 1847 O
prohibited 72 82 1848 1858 B-treatment
drugs 83 88 1859 1864 I-treatment
for 89 92 1865 1868 O
at 93 95 1869 1871 O
least 96 101 1872 1877 O
14 102 104 1878 1880 B-lower_bound
days 105 109 1881 1885 I-lower_bound
( 110 111 1886 1887 O
fruits 111 117 1887 1893 O
and 118 121 1894 1897 O
juices 122 128 1898 1904 O
for 129 132 1905 1908 O
at 133 135 1909 1911 O
least 136 141 1912 1917 O
7 142 143 1918 1919 B-lower_bound
days 144 148 1920 1924 I-lower_bound
) 148 149 1924 1925 O
prior 150 155 1926 1931 O
to 156 158 1932 1934 O
Day 159 162 1935 1938 O
1 163 164 1939 1940 O
of 165 167 1941 1943 O
FOLFIRI 168 175 1944 1951 B-treatment
+ 176 177 1952 1953 O
bevacizumab 178 189 1954 1965 B-treatment
initiation 190 200 1966 1976 O

Willing 0 7 1977 1984 O
to 8 10 1985 1987 O
undergo 11 18 1988 1995 O
UGT1A1 19 25 1996 2002 B-treatment
genotyping 26 36 2003 2013 I-treatment

Women 0 5 2014 2019 B-gender
of 6 8 2020 2022 O
childbearing 9 21 2023 2035 O
potential 22 31 2036 2045 O
and 32 35 2046 2049 O
male 36 40 2050 2054 B-gender
subjects 41 49 2055 2063 I-gender
must 50 54 2064 2068 O
agree 55 60 2069 2074 B-contraception_consent
to 61 63 2075 2077 I-contraception_consent
use 64 67 2078 2081 I-contraception_consent
adequate 68 76 2082 2090 I-contraception_consent
contraception 77 90 2091 2104 I-contraception_consent
for 91 94 2105 2108 O
the 95 98 2109 2112 O
duration 99 107 2113 2121 O
of 108 110 2122 2124 O
study 111 116 2125 2130 O
participation 117 130 2131 2144 O

patients 0 8 2145 2153 O
discovered 9 19 2154 2164 O
to 20 22 2165 2167 O
have 23 27 2168 2172 O
≥2 28 30 2173 2175 O
+ 30 31 2175 2176 O
proteinuria 32 43 2177 2188 B-clinical_variable
on 44 46 2189 2191 O
dipstick 47 55 2192 2200 B-treatment
urinalysis 56 66 2201 2211 I-treatment
at 67 69 2212 2214 O
baseline 70 78 2215 2223 O
should 79 85 2224 2230 O
undergo 86 93 2231 2238 O
a 94 95 2239 2240 O
24 96 98 2241 2243 B-upper_bound
hour 99 103 2244 2248 I-upper_bound
urine 104 109 2249 2254 O
collection 110 120 2255 2265 O
and 121 124 2266 2269 O
must 125 129 2270 2274 O
demonstrate 130 141 2275 2286 O
≤ 142 143 2287 2288 O
1 144 145 2289 2290 B-upper_bound
g 145 146 2290 2291 I-upper_bound
of 147 149 2292 2294 O
protein 150 157 2295 2302 O
in 158 160 2303 2305 O
24 161 163 2306 2308 B-upper_bound
hours 164 169 2309 2314 I-upper_bound

placement 0 9 2315 2324 O
of 10 12 2325 2327 O
a 13 14 2328 2329 O
vascular 15 23 2330 2338 B-treatment
access 24 30 2339 2345 I-treatment
device 31 37 2346 2352 I-treatment
, 37 38 2352 2353 O
within 39 45 2354 2360 O
7 46 47 2361 2362 B-upper_bound
days 48 52 2363 2367 I-upper_bound
prior 53 58 2368 2373 I-upper_bound
to 59 61 2374 2376 O
Day 62 65 2377 2380 O
1 66 67 2381 2382 O
of 68 70 2383 2385 O
FOLFIRI 71 78 2386 2393 B-treatment
+ 79 80 2394 2395 O
bevacizumab 81 92 2396 2407 B-treatment
initiation 93 103 2408 2418 O

